A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature.

Autor:	Ge TT; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.; Beijing University of Chinese Medicine, Beijing, China., Pan XJ; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.; Beijing University of Chinese Medicine, Beijing, China., Zuo XM; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Shi XG; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Wang YK; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Sun P; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Gao X; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Feng X; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Gao S; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China., Wang TS; Department of General Surgery, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2023 Dec 01; Vol. 102 (48), pp. e36297.
DOI:	10.1097/MD.0000000000036297
Abstrakt:	Background: Breast cancer is one of the most common type of cancers worldwide and remains a critical health issue. Although there are numerous treatment options for advanced metastatic breast cancer, the results are not satisfactory, particularly for triple-negative breast cancer. New treatment modalities need to be explored. Case Presentation: We present the case of a breast cancer patient with multiple metastases who achieved a good response and tolerance to the combination treatment of utidelone plus capecitabine. After being treated with 10 cycles of combined treatment, the patient is now in a good general condition with a progression-free survival time of 10 months. Conclusion: To our knowledge, this is the first report of utidelone plus capecitabine successfully treating a patient with heavily pretreated metastatic breast cancer. This combined treatment offers a new option for patients with multi-drug resistant breast cancer. Competing Interests: The authors have no funding and conflicts of interest to disclose. (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu